Nova Capital Management Limited (“Nova”), the specialist acquirer of corporate and private equity portfolios, has announced the sale of Sterilin Limited to Thermo Fisher Scientific Inc.

Sterilin is the UK’s leading manufacturer and supplier of single use plasticware for clinical and laboratory use in Life Sciences. It supplies a comprehensive range of swabs, petri dishes, pipettes, containers and Iwaki tissue culture products for medical and laboratory use. The company manufactures from a single site in South Wales, UK and sells its products directly and through distributors in the UK and through a global network of distributors.

Sterilin was part of a portfolio of six non-core businesses acquired from Barloworld of South Africa in November 2007.

Thermo Fisher Scientific Inc. is the world leader in serving science.

In announcing the sale, Adam Robson, Nova’s Operating Partner and Chairman of Sterilin, said: “Sterilin has undergone a significant turnaround and is now growing strongly following an extensive investment programme funded by Nova and the Welsh Assembly Government. Sterilin will provide a high value product platform for Thermo Fisher, which will be a good strategic owner, bringing strong manufacturing and commercial resources to build on Sterilin’s competencies. We feel the business will continue to be very successful.”

Nova was advised on the transaction by Travers Smith LLP.